Key Highlights

  • Amgen shares are trading at $410.87 in Thursday's session, down 2.52%.
  • The stock had rallied from September lows near $375 on Phase 3 dazodalibep data in Sjögren's disease and IMDELLTRA data in small cell lung cancer.
  • One brokerage lifted its price target to $500, while another stayed Neutral with a $405 target.
  • A 10-year Treasury Yield near 5.3% and a soft start to the fourth quarter are weighing on the shares.

Pipeline-Fueled Rally Meets a Valuation Check

Amgen (NASDAQ:AMGN) is pulling back in Thursday's session after a strong run, trading near $411 and underperforming the broader market. The stock climbed from September lows near $375 as a string of positive readouts rebuilt investor confidence, and some investors now question whether the gains have gone too far.

No company-specific negative has been identified. Rising bond yields and a soft start to the fourth quarter are adding pressure.

The Readouts Behind the September Rebound

Phase 3 data for dazodalibep in Sjögren's disease and data for IMDELLTRA in small cell lung cancer were the main drivers of the rebound. Together they supported the view that the pipeline reaches well beyond established products.

Analysts Split Between a $500 Target and a Neutral Stance

One brokerage lifted its target to $500, while another stayed Neutral with a $405 target, just below the current share price. Two research firms have also described the shares as overvalued, adding to the debate over how much of the pipeline success is already priced in.

MariTide and OASIZ 303 Updates Are the Next Catalysts

Investors are watching updates on the MariTide obesity program, the upcoming OASIZ 303 data and the full dazodalibep results. The stock trades within a 52-week range of $288.00 to $447.03 and offers a Dividend Yield of about 2.4%.